This February Sparsentan (FILSPARI©) received accelerated approval by the FDA as a medicine for treating proteinuria in adults with primary immunoglobulin A nephropathy (IgAN).

The drug molecule contains diazaspiro[4.4]nonen moiety in its backbone. To support your further research, we have made a set of Building Blocks that contain similar cores, which could be an excellent starting point for your research projects.

This is the first example of non-immunosuppressive therapy against such rare pathology as IgAN. Sparsentan works by blocking two types of receptors - endothelin type A (ETA) and angiotensin II subtype 1 (AT1), which are linked with the progression of kidney disease.